Choksi Laboratories Ltd

Choksi Laboratories Ltd, a player in the Healthcare Services sector, has touched a new 52-week low of Rs.81.85 today, marking a significant decline amid ongoing market pressures and sector underperformance. The stock’s recent performance highlights persistent challenges reflected in its valuation and financial metrics.

Choksi Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Choksi Laboratories Ltd, a key player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 17 Feb 2026. This shift reflects deteriorating technical indicators, stagnant financial performance, and a challenging valuation backdrop, signalling caution for investors amid underwhelming market returns and weak fundamental metrics.

Choksi Laboratories Ltd, a healthcare services company, has seen its investment rating downgraded from Strong Sell to Sell following a reassessment of its financial performance, valuation, technical indicators, and overall quality metrics. The downgrade reflects a cautious stance amid flat quarterly results, subdued financial trends, and mixed technical signals, despite some attractive valuation parameters.

Choksi Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Choksi Laboratories Ltd., a micro-cap contract testing and analytical services provider with a market capitalisation of ₹85.00 crores, reported a net profit of ₹0.31 crores for Q3 FY26 (October-December 2025), representing a sequential increase of 29.17% quarter-on-quarter but a substantial 181.82% surge year-on-year from ₹0.11 crores in Q3 FY25. However, the headline profit growth conceals troubling underlying trends, including persistent margin compression, an extraordinarily high tax rate of 65.56%, and declining operating efficiency that raise serious questions about the sustainability of this performance.

Choksi Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 19 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Choksi Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Choksi Laboratories, a player in the Healthcare Services sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory.

Choksi Laboratories, a key player in the Healthcare Services sector, has experienced a revision in its market assessment driven by nuanced changes across quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent shift in analytical perspective, providing investors with a comprehensive understanding of the company’s current standing.

Choksi Laboratories, a key player in the Healthcare Services sector, has exhibited a notable change in its financial trajectory during the quarter ended September 2025. The company’s recent quarterly results reveal a shift from a previously flat financial trend to a positive one, marked by significant movements in revenue and profitability metrics compared to historical performance.